Effect of Nusinersen on Adults With Spinal Muscular Atrophy
Study Identifier:
18-0149
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
EU CT Number:
N/A
Sponsor:
Northwell Health
Study Complete
Study Details
Medical Condition
- All Spinal Muscular Atrophies
Study Drug
- Drug: nusinersen
Date
Apr 2019 - Jul 2021
Patient Requirements
Sex: Female & Male
Age: 18 - 60 Years
Requirements Information
Inclusion and Exclusion Criteria
Inclusion Criteria
- Genetically confirmed 5q SMA
- ability to access intrathecal space for nusinersen injection
Exclusion Criteria
- Renal impairment
- thrombocytopenia
- inability to access intrathecal space by CT or flouro guided injection
Protocol Summary
Observational study of adult patients with spinal muscular atrophy types 2 and 3 receiving nusinersen
Trial Locations
Location
Status
Location
Northwell Health Neuroscience
Great Neck, New York, United States, 11021
Status
N/A
Contact Cure SMA
User Information
If you have general questions regarding clinical trials or would like to be added to the Cure SMA mailing list to receive communications regarding future registries, studies, or clinical trials in SMA, please fill out the form below. Fields marked with an asterisk (*) are mandatory.